Polatuzumab vedotin (Polivy)

Status:
Red
Decision Date:
June 2020
 

Comments

RED:

  • NICE TA649 - Polatuzumab vedotin with rituximab and bendamustine for refractory diffuse large B-cell lymphoma. (Decision date - October 2020) 
  • NICE TA874 - Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. (Decision date - April 2023)

Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app